{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:18:26Z","timestamp":1794709106325,"version":"4.9.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":891,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/14\/55\/30806"],"award-info":[{"award-number":["FS\/14\/55\/30806"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1194\/jlr.r083626","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T12:25:18Z","timestamp":1517228718000},"page":"577-585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["The role of lipoprotein (a) in chronic kidney disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Jemma C.","family":"Hopewell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.R083626_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2013the LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol. Microbiol. Scand."},{"key":"10.1194\/jlr.R083626_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1194\/jlr.R083626_bib3","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.2530631","article-title":"The mysteries of lipoprotein(a)","volume":"246","author":"Utermann","year":"1989","journal-title":"Science."},{"key":"10.1194\/jlr.R083626_bib4","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/01.ATV.0000144010.55563.63","article-title":"Lipoprotein(a): an elusive cardiovascular risk factor","volume":"24","author":"Berglund","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R083626_bib5","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein(a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R083626_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1194\/jlr.R051870","article-title":"Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis","volume":"57","author":"Thanassoulis","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R083626_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA."},{"key":"10.1194\/jlr.R083626_bib8","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO CKD Work Group","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1194\/jlr.R083626_bib9","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One."},{"key":"10.1194\/jlr.R083626_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet."},{"key":"10.1194\/jlr.R083626_bib11","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet."},{"key":"10.1194\/jlr.R083626_bib12","doi-asserted-by":"crossref","first-page":"e25920","DOI":"10.1371\/journal.pone.0025920","article-title":"Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis","volume":"6","author":"Mafham","year":"2011","journal-title":"PLoS One."},{"key":"10.1194\/jlr.R083626_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.ki.5002240","article-title":"Evidence mounts for a role of the kidney in lipoprotein(a) catabolism","volume":"71","author":"Albers","year":"2007","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1194\/jlr.R083626_bib15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","article-title":"In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib16","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/clinchem\/38.11.2244","article-title":"Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure","volume":"38","author":"Oida","year":"1992","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.R083626_bib17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/01.ATV.16.8.905","article-title":"Urinary excretion of apo(a) fragments. Role in apo(a) catabolism","volume":"16","author":"Kostner","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R083626_bib18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.V113507","article-title":"Lipoprotein(a) in the nephrotic syndrome: molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine","volume":"11","author":"Doucet","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R083626_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2362.1998.00319.x","article-title":"Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function","volume":"28","author":"Kostner","year":"1998","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1194\/jlr.R083626_bib20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/ajkd.2001.26889","article-title":"Renal handling of human apolipoprotein(a) and its fragments in the rat","volume":"38","author":"Reblin","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1194\/jlr.R083626_bib21","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0022-2275(20)37150-9","article-title":"Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation","volume":"38","author":"Kronenberg","year":"1997","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R083626_bib22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0272-6386(99)70147-2","article-title":"Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure","volume":"33","author":"Milionis","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"10.1194\/jlr.R083626_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.7326\/0003-4819-129-6-199809150-00006","article-title":"Increased serum lipoprotein(a) levels in patients with early renal failure","volume":"129","author":"Sechi","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1194\/jlr.R083626_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5527\/wjn.v4.i3.374","article-title":"Early renal failure as a cardiovascular disease: focus on lipoprotein(a) and prothrombotic state","volume":"4","author":"Catena","year":"2015","journal-title":"World J. Nephrol."},{"key":"10.1194\/jlr.R083626_bib25","doi-asserted-by":"crossref","first-page":"e114397","DOI":"10.1371\/journal.pone.0114397","article-title":"Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One."},{"key":"10.1194\/jlr.R083626_bib26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1053\/ajkd.2002.36319","article-title":"Association of kidney function with serum lipoprotein(a) level: the third National Health and Nutrition Examination Survey (1991\u20131994)","volume":"40","author":"Kovesdy","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"10.1194\/jlr.R083626_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R083626_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ajkd.2004.08.043","article-title":"Factors associated with lipoprotein(a) in chronic kidney disease","volume":"45","author":"Uhlig","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1194\/jlr.R083626_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/nep.12792","article-title":"Live donor study - implications of kidney donation on cardiovascular risk with a focus on lipid parameters including lipoprotein a","volume":"21","author":"Doucet","year":"2016","journal-title":"Nephrology (Carlton)."},{"key":"10.1194\/jlr.R083626_bib30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R083626_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1172\/JCI112406","article-title":"Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis","volume":"77","author":"Dieplinger","year":"1986","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R083626_bib32","first-page":"271","article-title":"High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis","volume":"38","author":"Shoji","year":"1992","journal-title":"Clin. Nephrol."},{"key":"10.1194\/jlr.R083626_bib33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/ki.1993.349","article-title":"Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with\/without diabetes mellitus","volume":"44","author":"Hirata","year":"1993","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib34","first-page":"609","article-title":"Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis","volume":"8","author":"Webb","year":"1993","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R083626_bib35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000188578","article-title":"Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature","volume":"70","author":"Gault","year":"1995","journal-title":"Nephron."},{"key":"10.1194\/jlr.R083626_bib36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3109\/0886022X.2010.486097","article-title":"Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease","volume":"32","author":"Aggarwal","year":"2010","journal-title":"Ren. Fail."},{"key":"10.1194\/jlr.R083626_bib37","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/ndt\/gfg276","article-title":"Lipoprotein (a) levels in those with high molecular weight apo (a) isoforms may remain low in a significant proportion of patients with end-stage renal disease","volume":"18","author":"Parsons","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R083626_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(96)90026-8","article-title":"Lipoprotein(a) in renal disease","volume":"27","author":"Kronenberg","year":"1996","journal-title":"Am. J. Kidney Dis."},{"key":"10.1194\/jlr.R083626_bib39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116213","article-title":"Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)","volume":"91","author":"Dieplinger","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R083626_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/0971-4065.107189","article-title":"Association between high molecular weight apolipoprotein isoforms and lipoprotein levels in advanced chronic kidney disease and the effect of hemodialysis","volume":"23","author":"Gambhir","year":"2013","journal-title":"Indian J. Nephrol."},{"key":"10.1194\/jlr.R083626_bib41","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","article-title":"Inflammation enhances cardiovascular risk and mortality in hemodialysis patients","volume":"55","author":"Zimmermann","year":"1999","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1194\/jlr.R083626_bib43","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1172\/JCI118487","article-title":"Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a)","volume":"97","author":"Mooser","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R083626_bib44","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/ndt\/gfg181","article-title":"Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function","volume":"18","author":"Cauza","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R083626_bib45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2362.2001.00811.x","article-title":"Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney","volume":"31","author":"Frank","year":"2001","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1194\/jlr.R083626_bib46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/dme.12862","article-title":"Lipoprotein(a) predicts a new onset of chronic kidney disease in people with type 2 diabetes mellitus","volume":"33","author":"Yun","year":"2016","journal-title":"Diabet. Med."},{"key":"10.1194\/jlr.R083626_bib47","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.09320913","article-title":"Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study","volume":"9","author":"Rahman","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R083626_bib48","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R083626_bib49","doi-asserted-by":"crossref","first-page":"11122","DOI":"10.1038\/ncomms11122","article-title":"Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA","volume":"7","author":"Kettunen","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1194\/jlr.R083626_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","article-title":"Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome","volume":"119","author":"Wanner","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1194\/jlr.R083626_bib51","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1523-1755.2004.00418.x","article-title":"The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome","volume":"65","author":"Kronenberg","year":"2004","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib53","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/clinchem\/35.10.2121","article-title":"Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin","volume":"35","author":"Kar\u00e1di","year":"1989","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.R083626_bib54","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.1993.357","article-title":"Lipoprotein(a) in nephrotic syndrome","volume":"44","author":"Stenvinkel","year":"1993","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000188426","article-title":"Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome","volume":"69","author":"Hong","year":"1995","journal-title":"Nephron."},{"key":"10.1194\/jlr.R083626_bib56","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/clinchem\/41.6.908","article-title":"Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria","volume":"41","author":"Joven","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.R083626_bib57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1523-1755.2004.00737.x","article-title":"Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?","volume":"66","author":"Kronenberg","year":"2004","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib58","first-page":"244","article-title":"Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria","volume":"9","author":"Gansevoort","year":"1994","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R083626_bib59","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1046\/j.1523-1755.1999.00489.x","article-title":"Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome","volume":"55","author":"Noto","year":"1999","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib60","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.V981474","article-title":"Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome","volume":"9","author":"De Sain-Van Der Velden","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R083626_bib61","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJM198506133122404","article-title":"The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity","volume":"312","author":"Appel","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R083626_bib62","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.ATV.14.9.1399","article-title":"Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation","volume":"14","author":"Kronenberg","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1194\/jlr.R083626_bib63","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.ejhg.5201016","article-title":"Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation","volume":"11","author":"Kronenberg","year":"2003","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1194\/jlr.R083626_bib64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0021-9150(99)00014-3","article-title":"Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up","volume":"144","author":"Kerschdorfer","year":"1999","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R083626_bib65","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R083626_bib66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000112225","article-title":"Effects of renal replacement therapy on plasma lipoprotein(a) levels","volume":"28","author":"Rosas","year":"2008","journal-title":"Am. J. Nephrol."},{"key":"10.1194\/jlr.R083626_bib67","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.ATV.14.9.1393","volume":"14","author":"Azrolan","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1194\/jlr.R083626_bib68","first-page":"863","article-title":"Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy","volume":"8","author":"Brown","year":"1993","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R083626_bib69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/clinchem\/38.3.353","article-title":"Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism","volume":"38","author":"Black","year":"1992","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.R083626_bib70","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/ndt\/7.7.636","article-title":"Lipid and lipoprotein (a) concentrations in renal transplant patients","volume":"7","author":"Webb","year":"1992","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R083626_bib71","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/ndt\/12.12.2673","article-title":"Urinary excretion of apo(a) in patients after kidney transplantation","volume":"12","author":"Kostner","year":"1997","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R083626_bib72","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1681\/ASN.V5122073","article-title":"The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients","volume":"5","author":"Hilbrands","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R083626_bib73","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(93)92616-2","article-title":"Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?","volume":"341","author":"Webb","year":"1993","journal-title":"Lancet."},{"key":"10.1194\/jlr.R083626_bib74","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000189549","article-title":"Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation","volume":"75","author":"Brown","year":"1997","journal-title":"Nephron."},{"key":"10.1194\/jlr.R083626_bib75","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"key":"10.1194\/jlr.R083626_bib76","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1194\/jlr.R083626_bib77","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R083626_bib78","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1194\/jlr.R052258","article-title":"Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans","volume":"57","author":"Graham","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R083626_bib79","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.R083626_bib80","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/joim.12187","article-title":"Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease","volume":"276","author":"Hopewell","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1194\/jlr.R083626_bib81","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R083626_bib82","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA."},{"key":"10.1194\/jlr.R083626_bib83","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R083626_bib84","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1681\/ASN.2004110922","article-title":"High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients","volume":"16","author":"Longenecker","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R083626_bib85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000077293","article-title":"Lipoprotein(a)-associated atherothrombotic risk in hemodialysis patients","volume":"24","author":"Emanuele","year":"2004","journal-title":"Am. J. Nephrol."},{"key":"10.1194\/jlr.R083626_bib86","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","article-title":"The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up","volume":"10","author":"Kronenberg","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R083626_bib87","first-page":"354","article-title":"Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy","volume":"10","author":"Webb","year":"1995","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R083626_bib88","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0009-3084(94)90165-1","article-title":"Lp(a) and premature mortality during chronic hemodialysis treatment","volume":"67\u201368","author":"Cressman","year":"1994","journal-title":"Chem. Phys. Lipids."},{"key":"10.1194\/jlr.R083626_bib89","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1046\/j.1523-1755.1999.07164.x","article-title":"Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients","volume":"71","author":"Ohashi","year":"1999","journal-title":"Kidney Int. Suppl."},{"key":"10.1194\/jlr.R083626_bib90","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.V8121889","article-title":"Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients","volume":"8","author":"Koch","year":"1997","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1194\/jlr.R083626_bib91","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA."},{"key":"10.1194\/jlr.R083626_bib92","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R083626_bib93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.jrn.2004.09.020","article-title":"Causes and consequences of the reverse epidemiology of body mass index in dialysis patients","volume":"15","author":"Kalantar-Zadeh","year":"2005","journal-title":"J. Ren. Nutr."},{"key":"10.1194\/jlr.R083626_bib94","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1525-139X.2007.00360.x","article-title":"What is so bad about reverse epidemiology anyway?","volume":"20","author":"Kalantar-Zadeh","year":"2007","journal-title":"Semin. Dial."},{"key":"10.1194\/jlr.R083626_bib95","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","article-title":"Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients","volume":"63","author":"Kalantar-Zadeh","year":"2003","journal-title":"Kidney Int."},{"key":"10.1194\/jlr.R083626_bib96","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/01.CIR.86.2.475","article-title":"Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients","volume":"86","author":"Cressman","year":"1992","journal-title":"Circulation."},{"key":"10.1194\/jlr.R083626_bib97","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1161\/01.CIR.0000038946.91899.BB","article-title":"Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the CHOICE study","volume":"106","author":"Longenecker","year":"2002","journal-title":"Circulation."},{"key":"10.1194\/jlr.R083626_bib98","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/01.ATV.14.9.1405","article-title":"Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease","volume":"14","author":"Kronenberg","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1194\/jlr.R083626_bib99","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ndt\/gfv428","article-title":"Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study","volume":"31","author":"Kollerits","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1194\/jlr.R083626_bib100","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R083626_bib101","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism."},{"key":"10.1194\/jlr.R083626_bib102","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R083626_bib103","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current therapies for lowering lipoprotein (a)","volume":"57","author":"van Capelleveen","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R083626_bib104","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R083626_bib105","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R083626_bib106","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R083626_bib107","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet."},{"key":"10.1194\/jlr.R083626_bib108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"\u2018LDL-C\u2019 = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.R083626_bib109","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.R083626_bib110","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R083626_bib111","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation."},{"key":"10.1194\/jlr.R083626_bib112","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R083626_bib113","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R083626_bib114","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R083626_bib115","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R083626_bib116","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet."},{"key":"10.1194\/jlr.R083626_bib117","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520339092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520339092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.R083626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T12:53:07Z","timestamp":1637412787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520339092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0022227520339092"],"URL":"https:\/\/doi.org\/10.1194\/jlr.r083626","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of lipoprotein (a) in chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1194\/jlr.R083626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Hopewell et al.","name":"copyright","label":"Copyright"}]}}